Cationic liposomes have been actively used as gene delivery vehicle because of their minimal toxicity, but their relatively low efficiency of gene delivery is the major disadvantage of these vectors. Recently, cysteine residue incorporation to HIV-1 Tat peptide increased liposomemediated transfection compared with unmodified Tat peptide. Therefore, we designed a novel modified Tat peptide having a homodimeric (Tat-CTHD, Tat-NTHD) and closed structure (cyclic Tat) simply by using the disulfide bond between cysteines to develop a more efficient and safe nonviral gene delivery system. The mixing of Tat-CTHD and Tat-NTHD with DNA before mixing with lipofectamine increased the transfection efficiency compared with unmodified Tat peptide and lipofectamine only in MCF-7 breast cancer cells and rat vascular smooth muscle cells. However, cyclic Tat did not show any improvement in the transfection efficiency. In the gel retardation assay, Tat-CTHD and Tat-NTHD showed more strong binding with DNA than unmodified Tat and cyclic Tat peptide. This enhancement was only shown when Tat-CTHD and Tat-NTHD were mixed with DNA before mixing with lipofectamine. The effects of Tat-CTHD and Tat-NTHD were also valid in the experiment using DOTAP and DMRIE instead of lipofectamine. We could not find any significant cytotoxicity in the working concentration and more usage of these peptides. In conclusion, we have designed a novel transfection-enhancing peptide by easy homodimerization of Tat peptide, and the simple mix of these novel peptides with DNA increased the gene transfer of cationic lipids more efficiently with no additional cytotoxicity.
The delivery of therapeutic drugs into the cell is generally one of the most important factors in recent drug development. Especially in the gene therapy for various diseases such as cancer [1, 8, 20, 25] and heart failure [13, 23] , it becomes more important because nucleic acids have the anionic charge and the targets of therapeutics are located around the nucleus. For the development of an optimal delivery vector for nucleic acid therapeutics and transfection of DNA in basic research, not only the efficiency but also safety should be kept in mind because of unwanted toxicity. Nonviral vectors such as cationic liposomes and polymers have been considered as more safe tools compared with viral vectors [33] . Among the nonviral vectors, cationic liposomes have been actively investigated because they have minimal toxicity and antigenic reactions [12] . Although cationic liposomes do not have tissue specificity, the enhanced permeability and retention effect of these can be effective as passive targeting [16] . However, the relatively low efficiency of gene delivery is the major drawback of these vectors [19] .
Cell penetrating peptide (CPP) or protein transduction domain (PTD) means a small peptide having ability to translocate cargoes across the plasma membrane into the cytoplasm. This property was renowned by the discovery of the Tat protein encoded by HIV-1 [6, 7] and nuclear localization sequence of SV-40 [14] . After these proteins, several peptides such as Antennapedia (Antp) [11] , Transportan [24] , and pVEC [5] were shown to have a similar ability. By means of further studies, it was revealed that the positive charge of truncated Tat peptide having basic amino acids with six arginines in the transduction domain is supposed to be involved in membrane translocation and in nuclear targeting [30] . This property of Tat peptide was used for the delivery of plasmid DNA [9, 10] and antisense oligonucleotides [2] . Furthermore, several reports have clearly demonstrated the ability of CPPs to enhance *Corresponding author Phone: +82-53-630-4335; Fax: +82-53-651-3651; E-mail: kodoh@ynu.ac.kr liposome-mediated transfection in cell cultures and in vivo upon local injection [9, 21, 28] . Others, however, showed that the addition of cysteine is needed for the sufficient transfection of DNA [15, 19] . Addition of terminal cysteines to lysine-rich peptides condensed DNA stably [18] , and disulfide bond formation was also shown to increase the stability of DNA-peptide interaction [17, 22] . Moreover, cysteine residue incorporation to Tat peptide increased liposome-mediated transfection more efficiently than unmodified Tat peptide [19, 32] . However, there was no report on homodimeric or cyclic Tat peptide using the disulfide bond. Therefore, we designed a novel modified Tat peptide having homodimeric and closed structure simply by using the disulfide bond between cysteines to develop a more efficient and safe nonviral gene delivery system. To this end, we evaluated the potency of these peptides in the MCF-7 breast cancer cell line and primary cultured rat vascular smooth muscle cells by luciferase and GFP gene expressions, and measured the mechanical interaction between these peptides and DNA using gel retardation assay.
MATERIALS AND METHODS

Cell Line and Cell Culture
Human breast cancer cell line MCF-7 was obtained from the Korean Cell Line Bank. The aortic vascular smooth muscle cells (VSMC) isolated from 11-week-old male Sprague-Dawley rats were generously provided by Hyoung Chul Choi (Department of Pharmacology, School of Medicine, Yeungnam University, Korea). Cells were grown in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. The cells were maintained in a humidified incubator with 5% CO 2 at 37 o C. The cell culture reagents, including FBS, were purchased from Welgene (Korea).
Peptide Synthesis and Modification
The peptide used in the present study was derived from the Tat protein of HIV-1. The Tat peptide corresponds to the nuclear localization signal (NLS) sequence of 12 amino acids (49-60; RKKRRQRRRPPQ). The peptide was modified at either the N-or C-terminus by the addition of cysteine ( Table 1 ). All of the peptides described in this study were synthesized by Peptron, Inc. (Korea). Briefly, peptides were synthesized by the Fmoc-SPPS solid phase peptide synthesis method using APS-48S (Peptron Inc., Korea) and purified by reverse-phase HPLC using a Vydac Everest C18 column (250 mm × 22 mm, 10 µm). Elution was carried out with a wateracetonitrile linear gradient [3~40% (v/v) of acetonitrile] containing 0.1% (v/v) trifluoroacetic acid. For the formation of homodimeric peptides, each monomeric peptide was dissolved in 0.1 M ammonium bicarbonate in acetonitrile:water (v:v=1:1) (1 mg/ml). The reaction mixture was stirred at atmosphere until the reaction was complete. The reaction was monitored by Ellman test [3] and LC/MS. The mixture was lyophilized and then purified by reverse-phase HPLC. The average homodimeric conjugation yield was over 80% by HPLC monitoring of completed reaction samples (data not shown). The molecular weights of the purified peptide were confirmed using LC/MS (Agilent HP1100 series, USA). Purified peptides were resuspended at a concentration of 10 µg/µl in distilled water and kept at -70 o C prior to further use.
Formation of Complex and Transfection
The pcDNA-Luc containing the firefly luciferase reporter gene and the plasmid coding for green fluorescent protein (pCMVTnT-GFP) were obtained from Welgene (Korea). DNA plasmids were amplified in the Escherichia coli XL1-Blue strain and purified by a maxi-kit (Qiagen Inc., USA) according to the manufacturer's instructions. DNA purity was determined by agarose gel electrophoresis and by measuring the optical density (OD). DNA having OD260/OD280≥1.8 was used in this study. The pcDNA-Luc and pCMVTNT-GFP were used at a concentration of 0.3 µg/well unless otherwise specified. Plasmid DNA, peptide, and liposome solution were prepared in a transfection optimizing medium (TOM, Welgene Co., Korea) in 50 µl volume, and plasmid DNA was first mixed with the peptide. After 10 min incubation of the DNA:peptide complex, we mixed this complex with liposome and incubated it for 15 min more at room temperature. Twenty-four hours prior to transfection, the cells were transferred to 48-well culture plates at a density of 40,000 cells/well for MCF-7 and VSMC. Thirty minutes before transfection, the medium was removed and the cells from each well were briefly washed with 100 µl of sterile phosphate-buffered saline (PBS); then 150 µl of TOM was added to each well. The wells then received 150 µl of DNA:peptide:lipid complex, and the plates were incubated for 4 h. An additional 300 µl of medium (20% FBS) was added to each well so as to achieve a final serum concentration of 10%, and the plates were incubated for a further 24 h. Commercial liposomes were also tested in order to reveal the best conditions within the range of the manufacturer's protocol, and used here in those optimal conditions. Luciferase Assay and GFP Expression Twenty-four hours after transfection, the medium was aspirated and the wells were washed twice with 200 µl of ice-cold PBS. To each well, 100 µl of 1× reporter lysis buffer (Promega Corp., USA) was added and the cells were lysed for 1 h in an ice tray. The cell lysates were completely collected into Eppendorf tubes and centrifuged (12,000 rpm, 4 o C) for 5 min. The supernatant was transferred to Eppendorf tubes in ice and used for luciferase and protein assays. For the luciferase assay, 20 µl of cell lysate was transferred to a white opaque 96-well plate for measurement and assessed directly by means of a LMax II 384 luminometer (Molecular Devices Corp., USA) using a luciferase assay kit (Promega Corp., USA). The protein content was quantified using a bicinchoninic acid (BCA) assay (Pierce, USA). The BCA assay was prepared as specified by the manufacturer. Forty µl of cell lysate was mixed with 1 ml of BCA reagent in an acrylic cuvette, and the solution was incubated for 1 h at 37 o C. The light absorption of the solution was then read at 562 nm by means of a DU-600 spectrophotometer (Beckman Coulter, USA), and the protein content was estimated by a comparison with bovine serum albumin standards. The luciferase efficiency was normalized by the protein content and expressed as relative luminescence units/µg of protein (RLU/µg protein). To observe GFP expression, 24 h after transfection, the medium was removed and the cells were rinsed twice with PBS. Fluorescence protein was observed on a Nikon ECLIPSE TE300 fluorescence microscope (Japan).
Gel Retardation Assay
For agarose gel retardation assays, 0.25 µg of pcDNA-Luc was mixed with peptide and/or cationic lipid at various concentrations. Ten µl of DNA:peptide and DNA:peptide:lipid complex solution was mixed with 2 µl of 6× loading buffer and loaded onto a 1% agarose gel containing ethidium bromide. Electrophoresis was carried out for 45 min in 1× TBE running buffer solution. Images were taken using a UV light illuminator.
Cell Viability Assay
According to the transfection protocol described above, 24 h after transfection, 20 µg of MTT in 20 µl of PBS was added to each well and the plates were then incubated for 3 h. The medium was carefully removed and 200 µl of dimethyl sulfoxide (DMSO) was added to each well. The reduced crystal in violet was completely dissolved in DMSO and then the absorbance of the solution was determined at 550 nm. The cells treated with only pcDNA-Luc solution without liposome were used as the OD control. Cell viability was calculated by the following equation: Cell viability (%)=OD sample/OD control×100
RESULTS AND DISCUSSION
Modified Tat Peptides Enhanced Transfection Efficiency of Cationic Lipid
HIV-1 Tat peptide is renowned to enhance cellular uptake of nucleic acids and proteins. In addition, the combination of cationic lipid and terminal cysteine modified Tat peptide showed greater enhancement of DNA transfection compared with cationic lipid alone [19, 32] . We designed the modified peptide derived from HIV-1 Tat peptide by homodimerization and circular formation using the disulfide bond to develop a more effective peptide having ability to enhance transfection of DNA. Among these peptides, C-and N-terminal disulfide homodimers (Tat-CTHD and Tat-NTHD) increased the transfection efficiency more effectively in MCF-7 breast cancer cells and primary cultured vascular smooth muscle cells (VSMC) (Fig. 1) . When the ratio of cationic lipid (Lipofectamine) was fixed to 1:5 (DNA:lipid), the addition of these two modified Tat peptides showed increased luciferase activity compared with unmodified Tat peptide addition and lipid alone. Interestingly, the addition of Tat-CTHD and Tat-NTHD showed similar enhancement of transfection efficiency at 1:3 and 1:5 (DNA:peptide) in MCF-7, but the more addition of peptide (1:5) increased the transfection efficiency more effectively in VSMC. More addition of homodimeric Tat peptides than 1:5 (DNA:peptide), however, did not show more increase of luciferase activity. Unmodified Tat demonstrated marginal enhancement of transfection efficiency only at 1:5 (DNA:peptide) in VSMC. However, cyclic Tat did not show any improvement in the transfection efficiency compared with unmodified Tat peptide and lipid alone. Transfection-enhancing effects of Tat-CTHD and Tat-NTHD were also observed by the expression of GFP protein using fluorescent microscopy after transfection of plasmid DNA expressing GFP to MCF-7 cells. Microscopic observation obviously showed the increased number of GFP-positive cells in the wells transfected with the combination of modified Tat peptides and lipid (Fig. 2) .
In another study using modified Tat peptide by cysteine addition, DNA and peptide were mixed and stabilized by air bubbling, and the authors expected that the disulfide bonds established in the DNA and peptide would stabilize this complex and protect the DNA. After entrance into the cell, the reducing environment of inside the cell was expected to release the DNA from the complex [19, 32] . By contrast, DNA and modified Tat peptide were simply mixed before the mixing with cationic lipid in our study. In spite of the simple synthesis and simple preparation, we achieved satisfactory results. Consistent with other studies [19, 32] , we also could not find any meaningful transfection using DNA with modified peptide alone without cationic lipid (data not shown).
Interaction of DNA and Peptides
In the case of insufficient transfection with DNA and CPP without cationic liposomes or polymers, it was attributed to the poor binding to the cell membrane caused by insufficient interaction of peptide with DNA [15, 27] . For cationic lipid-and polyamine-mediated transfection, the first step is believed to be the electrostatic interaction between the DNA:carrier complex and the anionic plasma membrane [29] . To determine this interaction of DNA and modified peptides, DNA retardation was measured on the agarose gel with the DNA:peptide and DNA:peptide:lipid complexes at different DNA:peptide ratios. The mobility of plasmid DNA was reduced with the increasing ratio of peptide. Tat-CTHD and Tat-NTHD could prevent the moving of DNA with a smaller amount than Tat peptide and cyclic Tat, indicating a more efficient neutralization of DNA (Fig. 3) .
We also tested whether the change of mixing order would affect the transfection efficiency. The measured luciferase assay results indicated that we should make the complex of DNA and peptides before mixing with cationic lipids to increase the transfection efficiency compared with vice versa (Fig. 4A ). This result is in accord with other data [19, 26] , and definitely demonstrates that the interaction of DNA and peptide is one of the most important factors determining the success of the enhancement of transfection efficiency. Moreover, this result together with the gel retardation assay implies that the important mechanism of Binding of peptides with DNA (pcDNA-Luc) was measure by the agarose gel retardation assay. DNA:peptide and DNA:peptide:lipid complex solution mixed at various ratios were loaded onto a 1% agarose gel containing ethidium bromide, and images were taken using a UV light illuminator.
these peptides is the condensation of DNA. We assume that the nuclear localizing action of these peptides will start after the DNA:peptide:lipid complex enters into the cell, as suggested by others [26, 32] . It was presumed that the improvement of the transfection efficiency by modified Tat peptide is caused by the enhanced endocytosis and increased endosomal escape [31] . The change of zeta potential and complex size that resulted from the addition of modified Tat peptide also may be the possible reason of this enhancement observed in the experiment using homodimerization by cysteine, although further studies are needed to verify this idea. From good binding affinity to integin with a stable structure of cyclic RGD peptide (cRGD) [4] , we designed the cyclic Tat to know the potency of this structure. However, cyclic Tat did not demonstrate increased binding activity with DNA, and failed to enhance gene delivery efficiency.
Transfection-Enhancing Effects of Modified Tat Peptide on Other Lipids
This enhancement effect of modified Tat peptides with Lipofectamine prompted us to examine the effect of these peptides on different types of cationic lipids. Therefore, we investigated the effect of modified Tat peptides addition on the transfection efficiency of DOTAP and DMRIE by luciferase assay. The addition of modified Tat peptide before mixing DNA with DOTAP and DMRIE also increased the transfection efficiency in MCF-7 cells (Fig. 4B ).
Unremarkable Cytotoxicity of Modified Tat Peptide
We measured the effects of novel homodimeric Tat peptide on cell viability, although Tat peptide is known to have no toxicity [28, 30] . MCF-7 cells were transfected with various doses of complexes from 1:1~1:20 (DNA:peptide) for 24 h at the fixed concentration of DNA:lipid (1:5). The modified Tat peptide did not show any significant effects on the cell viability up to the 1:20 (DNA:peptide) ratio (Table 2 ).
In conclusion, we designed a novel transfection-enhancing peptide by easy homodimerization of Tat peptide, and the simple mix of these novel peptides with DNA increased the gene transfer of various cationic lipids more efficiently with no additional cytotoxicity. Cells were treated with the concentration of transfection protocol at the above weight ratio. Cell viability was measured by MTT assay in MCF-7 cells. The data are viability compared with non-treated control and represent the mean ±SD of triplicate experiments.
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